Please assess the completion status of the following clinical trial:

Trial Title: Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically stable Type 2 Diabetes Mellitus~* Females without childbearing potential~* Body mass index (BMI) \>= 18.5 kg/m2 and \<= 39.9 kg/m2~* Hemoglobin A1c levels \>= 6.5% and \<= 10%~* Fasting blood glucose levels \>= 140 mg/dL and \<= 270 mg/dL~* Systolic blood pressure \>= 95 mmHg and \<= 160 mmHg, and diastolic blood pressure \>= 50 mmHg and \<= 100 mmHg, and pulse rate \>= 50 bpm~* Patients who have not been administered anti-diabetic medication within 2 weeks Prior to dosing~* Medicines if necessary for Hypertension or Dyslipidemia should be administered with stable dosage at least 3 months~* Treatment with diet and exercise should be unchanged for more than 3 months~Exclusion Criteria:~* Type 1 Diabetes Mellitus or Secondary Diabetic Mellitus~* History of diabetic complications which need treatment~* Treatment with insulin, thiazolidinediones, thiazide diuretics、beta blockers or systemic steroids within 3 months prior to informed consent~* Serum creatinine \> upper limit of the normal range~* Patients with significant complications

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- TA-7284 (Type: EXPERIMENTAL): None
- Placebo of TA-7284 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).